

**ERRATA SHEET
TO THE ENDOCRINOLOGIC AND METABOLIC DRUGS
ADVISORY COMMITTEE BRIEFING MATERIALS**

EMPAGLIFLOZIN 2.5 MG TABLET

**INDICATION: Adjunct to insulin therapy to improve
glycemic control in adults with type 1 diabetes**

OCTOBER 23, 2019

AVAILABLE FOR PUBLIC RELEASE

Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Rd
Ridgefield, CT 06877-0368
(203) 798-9988

Section 8.6.1.1 of the briefing materials (page 63)

The captions for Figures 23 and 24 are incorrect. The corrected captions are shown below.

Figure 23 Change from baseline in HbA_{1c} at Week 26 by baseline eGFR in EASE-3





Figure 24 Change from baseline in HbA_{1c} at Week 26 by time since diagnosis of type 1 diabetes in EASE-3



Section 8.7 of the briefing materials (page 75)

The in-text reference to Table 22 (shown on page 76 of the briefing materials) incorrectly links to Figure 22 on page 58.